Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Postprandial Insulin Lispro Is Effective But May Impair Long-Term Glycaemic Control

        A DGReview of :"Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with Type 1 diabetes"
        Diabetic Medicine

        03/29/2004
        By Emma Hitt, PhD


        Administering insulin lispro postprandially appears to be a useful strategy for patients with an unpredictable eating schedule, although for continuous long-term use, the risk of poorer glycaemic control may need to be considered.

        Postprandial insulin administration allows adjustment of the insulin dose according to the calories actually ingested. Therefore, this may be a useful strategy for some patients with unpredictable schedules, such as children, frequent travellers, or those with decreased gastric emptying rate.

        Guntram Schernthaner, MD, with the Department of Internal Medicine, at the Rudolfstitung Hospital, in Vienna, Austria, and colleagues conducted a 6-month, crossover study comparing the metabolic effects of routine use of preprandial versus postprandial injection of bolus insulin lispro.

        Thirty-one patients with type 1 diabetes injected insulin lispro either preprandially or postprandially for a 3-month period. They then switched and to the alternate regimen for a further 3 months. The researchers measured glycosylated haemoglobin (HbA1c), fructosamine, and 8-point self-determined blood glucose profiles.

        With preprandial insulin lispro, mean HbA1c decreased slightly from baseline whereas it increased slightly with postprandial administration, and this resulted in a significant difference in final HbA1c level (P = .008).

        Mean fructosamine also decreased slightly with preprandial insulin lispro but was almost unchanged with postprandial insulin. Overall daily blood glucose was similar between the two treatments (P = .312). However, mean preprandial glucose was lower (P = .026), whereas mean postprandial glucose was higher (P = .031) with postprandial insulin lispro administration.

        In addition, mean blood glucose excursions were higher with postprandial compared with preprandial insulin lispro, indicating greater daily fluctuations. No difference in incidence of hypoglycaemia was observed with the two treatment regimens, however.

        The researchers conclude that postprandial administration of insulin lispro "appears to be an acceptable treatment regimen since it adequately controls blood glucose."

        However, they point out that "the daily fluctuations appear to be increased and this could result in increasing HbA1c levels with continuous postprandial administration for long periods. Therefore, HbA1c should continue to be monitored and the benefits of postprandial administration may have to be balanced against less beneficial glycaemic control," they suggest.



        Diabet Med 2004 Mar;21:3:279-84. "Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with Type 1 diabetes"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send